Previous 10 | Next 10 |
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer,...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer,...
F-star Therapeutics, Inc. (FSTX) Q2 2021 Earnings Conference Call August 12, 2021, 09:00 AM ET Company Participants Lindsey Trickett - VP of IR Eliot Forster - CEO Darlene Deptula-Hicks - CFO Conference Call Participants Daina Graybosch - SVB Leerink Matt Phipps - William Blair Hartaj Singh -...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with canc...
Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company ded...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, ...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today ...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies...
Gainers: Aerpio Pharmaceuticals (ARPO) +54%, GBS (GBS) +25%, 9 Meters Biopharma (NMTR) +19%, Alterity Therapeutics (ATHE) +10%, F-star Therapeutics (FSTX) +9%.Losers: Virpax Pharmaceuticals (VRPX) -13%, Nephros (NEPH) -12%, ...
metamorworks/iStock via Getty Images F-star Therapeutics (FSTX) has added ~14.3% in the pre-market after announcing a licensing agreement with AstraZeneca (AZN) for next-generation Stimulator of Interferon Genes ((STING)) inhibitor compounds. Per the terms, Anglo-Swedish d...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can...